Asche C, Di Bidino R, Burrell, A et al. Methodological Frameworks for Economic Evaluation of Digital Health Interventions, Value in Health 2026, in press, published online June 1, 2026
Kinsella F, Quignot N, Read SH, Gusto G, Kikuchi K, Reichenbach D, Burrell A et al. Quantifying the Clinical and Economic Burden of Graft-versus-Host Disease following Allogeneic Haematopoietic Stem Cell Transplantation in England: A Retrospective Cohort Study. Adv Ther (2025). https://doi.org/10.1007/s12325-025-03355-9
Champion A, Burrell A, Holtorf AP, et al. Toward a Common Ground for Defining Digital Health Interventions, Mapping Digital Health Frameworks to PICOTS-ComTeC: An ISPOR Special Interest Group Report. Value Health. Published online August 5, 2025. doi:10.1016/j.jval.2025.07.022
Burrell A, Guest column, Four steps to make a Business Case for Digital Endpoints, Clinical Tech Leader, September 12th 2025 available online at https://www.clinicalleader.com/doc/steps-to-make-a-business-case-for-digital-endpoints-0001
Burrell A, Guest column, Where the FDA and EMA Stand on Digital Endpoints, Clinical Tech Leader, August 22nd 2025 available online at https://www.clinicalleader.com/doc/where-the-fda-and-ema-stand-on-digital-endpoints-0001
Burrell A, Guest column, Can Digital Endpoints Really Accelerate Clinical Trials?, Clinical Tech Leader, August 8th, 2025 available online at https://www.clinicalleader.com/doc/can-digital-endpoints-really-accelerate-clinical-trials-0001
Zrubka Z, Champion A, Holtorf AP, Di Bidino R, Earla JR, Boltyenkov AT, Tabata-Kelly M, Asche C, Burrell A. The PICOTS-ComTeC Framework for Defining Digital Health Interventions: An ISPOR Special Interest Group Report. Value Health. 2024 Apr;27(4):383-396. doi: 10.1016/j.jval.2024.01.009
Pauly N, Burrell A, Drelich D et al, Assessing health care resource use, outcomes and costs among Medicaid beneficiaries receiving factor IX prophylaxis for hemophilia B, Journal of Managed Care & Specialty Pharmacy, 2024, Vol 30, Number 10; 1095-1105 https://www.jmcp.org/doi/full/10.18553/jmcp.2024.23328
Burrell A, expert interview for “Defining Digital Health and Getting Clarity for HEOR”, Value and Outcomes Spotlight March April 2024 available online at https://www.ispor.org/publications/journals/value-outcomes-spotlight/vos-archives/issue/view/defining-digital-health—getting-clarity-for-heor/defining-digital-health–and-getting-clarity-for-heor
Holtick U, Quignot N, Kapso-Kapnang R, Reichenbach D, Kelly M, Burrell A, et al, Clinical and Economic Burden Associated With Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation in Germany, Transplantation Proceedings 2024, 56:1, 191-200, https://doi.org/10.1016/j.transproceed.2023.11.032.
Moss E, Burrell A, Lee J, Reichenbach D et al, Economic and humanistic burden in kidney transplant rejection: a literature review, Expert Review of Pharmacoeconomics & Outcomes Research 2024, 24:3, 343-352, DOI: 10.1080/14737167.2024.2305140
Michonneau, D, Quignot, N, Jiang, H, Reichenbach D, Kelly M, Burrell A et al. Clinical and economic burden associated with graft-versus-host disease following allogeneic hematopoietic cell transplantation in France. Bone Marrow Transplant 58, 514–525 (2023). https://doi.org/10.1038/s41409-023-01930-8
Zah V, Burrell A, Asche C, Zrubka Z. Paying for Digital Health Interventions – What Evidence is Needed. Act Polytechnica Hungarica Vol. 19, No. 9, 2022, DOI: 10.12700/APH.19.9.2022.9.10 available at http://acta.uni-obuda.hu/Zah_Burrell_Asche_Zrubka_127.pdf
Burrell A Zrubka Z, Champion A et al , How Useful Are Digital Health Terms for Outcomes Research? An ISPOR Special Interest Group Report, Value in Health 2022, Volume 25, Issue 9, 1469 – 1479, DOI: 10.1016/j.jval.2022.04.1730
Di Bidino R, Burrell A, Zrubka Z, Digital health e dintorni: le parole che non concordana, About Pharma published 12th September 2022, available at https://www.aboutpharma.com/digital-health/digital-health-e-dintorni-le-parole-che-non-concordano/
Burrell A, expert interview for “why biosimilars adoption is slow in the USA and can something be done to boost uptake” MedCity News, October 1st 2019 available at https://medcitynews.com/2019/10/why-biosimilars-adoption-is-slow-in-the-u-s-and-can-something-be-done-to-boost-uptake/
Burrell A, Can Real World Evidence Improve Market Access for Biosimilars in the US?, Guest Column, Biosimilar Development, June 29th 2018 available at https://www.biosimilardevelopment.com/doc/can-real-world-evidence-improve-market-access-for-biosimilars-in-the-u-s-0001
Burrell A, How Recent Regulatory and Payer Development will Impact US Biosimilar Access, Guest column, Biosimilar Development June 19th, 2018 available at https://www.biosimilardevelopment.com/doc/how-recent-regulatory-and-payer-developments-will-impact-u-s-biosimilar-access-0001
Burrell A, Market Access Impediments: Where should Biosimilars Go From Here? Guest Column, Biosimilar Development, June 12th 2018 available at https://www.biosimilardevelopment.com/doc/market-access-impediments-where-should-biosimilars-go-from-here-0001
Burrell A, How Should Biosimilar Companies Approach Real-World Evidence? Guest Column, Biosimilar Development April 24th 2018 available at https://www.biosimilardevelopment.com/doc/how-should-biosimilar-companies-approach-real-world-evidence-0001
Burrell A, From volume to value: Using payer insights to increase sales effectiveness, available at http://goo.gl/gez2KD
Burrell A, Leadership Exchange Panelist for “Reconcilable Difference” available at http://media.mmm-online.com/documents/152/leadership_exchange%E2%80%94reconcilab_37954.pdf
Burrell A, The App Gap; why there are so many apps and wearables and so few successes, available at http://www.hsandm-digital.com/hsandm/may_june_2015/?pm=2&u1=friend&article_id=619933&pg=NaN#pgNaN
Cramer JA, Roy A, Burrell A et al. Medication Compliance and Persistence: Terminnology and Definitions Value in Health 20028, Voll 11, Issue 1, p44-47
Brown RE, Burrell A, The economic advantages of response in the treatment of advanced breast cancer, Journal of Medical Economics 12/2008; 2(1-4):57-63.
Phillips CJ, Burrell A, Moore A, Bates GJ, Commins D, Mucodyne: the economics of preventing surgery for grommets, Journal of Medical Economics 12/2008; 2(1-4):167-176.
Green C, Kiebert G, Murphy C, Mitchell JD, O’Brien M, Burrell A, Leigh PN, Patients’ health-related quality-of-life and health state values for motor neurone disease/amyotrophic lateral sclerosis, Quality of Life Research 07/2003; 12(5):565-574
Anderson DJ, Burrell A, BearneA, Cost associated with venous thromboembolism treatment in the community, Journal of Medical Economics Jan 2002, Vol. 5, No. 1-4, Pages 1-10:
Brown RE, Hutton J, Burrell A, Cost Effectiveness of Treatment Options in Advanced Breast Cancer in the UK, PharmacoEconomics 01/2001; 19(11):1091-1102.
Bose U, Ladkani D, Burrell A, Sharief M, Cost-effectiveness analysis of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis, Journal of Medical Economics 2001; 4(1-4):207-219
Kiebert GM, Green C, Murphy C, Mitchell JD, O’Brien M, Burrell A, Leigh PN, Patients’ health-related quality of life and utilities associated with different stages of amyotrophic lateral sclerosis., Journal of the Neurological Sciences 11/2001; 191(1-2):87-93.
Jansen RB, Capri S, Nuitjen MJC, Burrell A, Marini MG, Hardens M, An economic evaluation of meloxicam 7.5mg vs diclofenac 100mg retard in the treatment of osteoarthritis: a cross national assessment for France, Italy and the UK, British Journal of Medical Economics 11/1997:9-22
Jansen RB, Burrell A, Nuitjen MJ, et al. An economic evaluation of meloxicam 7.5 mg versus diclofenac 100 mg retard in the treatment of osteoarthritis in the UK: a decision analysis model based on gastrointestinal complications. British Journal of Medical Economics 1996;10:247-62.